View our annual report summarizing our financial and operational performance for the past year.
View our proxy statement outlining key information about the upcoming shareholder meeting.
Request paper copies of the above proxy materials online now, via email or via phone
by dialing 866-648-8133.
Your vote is important! Please be sure to vote your shares online now or via phone by dialing 866-230-6343.
May 22, 2025
9:00 a.m. Eastern Time
We envision the full potential of complement therapeutics lies within the power of selectivity. Our lead antibody, DNTH103, is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections to improve the lives of patients.